We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 0.41% | 36.75 | 36.70 | 36.95 | 37.10 | 36.35 | 36.70 | 997,061 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 215.88 | 198.24M |
TIDMAPH
RNS Number : 3108P
Alliance Pharma PLC
09 October 2019
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Director's Dealing
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has received notice that on 7 October 2019, Peter Butterfield, Chief Executive Officer of Alliance, exercised unapproved share options over 3,137,546 ordinary shares of 1p each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The average exercise price was 34.5 pence.
Following the exercise, on 7 October 2019, Mr Butterfield sold 2,791,546 Ordinary Shares at a price of 73.5 pence per share. Following these transactions, Mr Butterfield's total beneficial interest in the Group is 374,376 Ordinary Shares, representing approximately 0.07 per cent. of the Group's issued share capital.
The 3,137,546 Ordinary Shares will be admitted to trading pursuant to an existing block listing, and will rank pari passu with the existing Ordinary Shares in issue.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated a) Name Peter Butterfield -------------------------- ------------------------------------------------- 2 Reason for the notification ----------------------------------------------------------------------------- a) Position/status Chief Executive Officer -------------------------- ------------------------------------------------- b) Initial notification Initial Notification /Amendment -------------------------- ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name ALLIANCE PHARMA PLC -------------------------- ------------------------------------------------- b) Legal Entity 213800RYIWZA4Q5WPZ13 Identifier -------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of Ordinary shares of 1 pence each the financial instrument, type of instrument GB0031030819 Identification code -------------------------- ------------------------------------------------- b) Nature of the a) Exercise of options transaction b) Sale of Ordinary Shares -------------------------- ------------------------------------------------- c) Currency GBP -------------------------- ------------------------------------------------- d) Price(s) and Price(s) Volume(s) volume(s) -------------------------- ------------------------------- ---------------- a) 34.5 pence a) 3,137,546 b) 73.5 pence b) 2,791,546 -------------------------- ------------------------------- ---------------- e) Aggregated information a) 3,137,546 Ordinary Shares, weighted average - Aggregated exercise price of 34.5 pence per Ordinary volume Share. - Price b) 2,791,546 Ordinary Shares, sold at a price - Aggregated of 73.5 pence per Ordinary Share, totalling total GBP2,051,786.31. -------------------------- ------------------------------------------------- f) Date of the transaction 7 October 2019 -------------------------- ------------------------------------------------- g) Place of the London Stock Exchange, AIM transaction -------------------------- -------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970 Corporate Finance: Daniel Adams / Ed Thomas Corporate Broking: Patrick Robb / Tejas Padalkar
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHMMMGGGLGGLZM
(END) Dow Jones Newswires
October 09, 2019 06:14 ET (10:14 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions